Pfizer Inc. (PFE) Earnings Call Transcripts

Pfizer Inc.'s Latest Earnings Call - Q2 FY2026

In Q2 2026, Pfizer Inc. reported revenues of $15 billion, exceeding expectations and reflecting a year-over-year operational increase of 1%. Adjusted diluted EPS was $0.77, also above consensus estimates, driven by strong commercial execution and cost management. Management raised the midpoint of their full-year revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion, while reaffirming adjusted diluted EPS guidance of $2.80 to $3.00, absorbing an unfavorable impact from a recent acquisition. The strong performance in non-COVID products and ongoing cost savings initiatives signal a positive outlook for the company moving forward.

Reported metrics

Guidance from management

Pfizer raised its full-year revenue guidance midpoint by $500 million to a range of $60.5 billion to $62.5 billion, while reaffirming adjusted diluted EPS guidance of $2.80 to $3.00, absorbing an unfavorable impact from a recent acquisition.

What management said

And I want also to emphasize that there is a very important study that we have initiated that if positive, will be very exciting, which is in bladder-sparing opportunity so that those patients will not have to go through this horrible operation. That will be a really big deal, if we will achieve it.

Thank you very much. I'll start. Thank you for the question. This trial is definitely fully enrolled, and we have not reached the events for the study, just to confirm. So events not reach as outlined in the statistical analysis plan.

What analysts pressed on

Analysts expressed concerns regarding the impact of low COVID-19 infection rates on future revenues, particularly for Paxlovid. There were also questions about how the company plans to navigate the upcoming loss of exclusivity (LOE) for key products and the potential implications for growth.

Main topics on the call

• Revenue Growth from Acquired Products — Pfizer's acquired products saw a remarkable 25% operational revenue growth, excluding certain onetime items. Management stated, "We view our Seagen, Metsera and Biohaven transactions as transformative opportunities for P...
• Pipeline Advancements — The company is advancing its R&D pipeline with significant milestones, including 10 Phase III studies planned for 2026. Management noted, "Our pipeline progress through the first half of the year reflects our discipline ...
• Cost Management Initiatives — Pfizer expects an additional $1 billion in savings from ongoing cost realignment programs, totaling $6.7 billion in net savings through 2029. Management emphasized that "financial discipline and cost management is allowi...
• COVID-19 Revenue Impact — Management lowered expectations for COVID-19 revenues to approximately $4 billion, down from $5 billion, due to low infection rates. They indicated that "low COVID-19 incidence could continue to limit Paxlovid utilizatio...

Read the full Pfizer Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 114 Pfizer Inc. earnings call transcripts on record, spanning January 14, 2020 to August 4, 2026. Based on this history, Pfizer Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PFE

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

114

First call

January 14, 2020

Most recent

August 4, 2026

Reporting cadence

quarterly